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As there are several thousands of rare disorders and
only some tents of orphan drugs authorized in Europe,
off-label use of medicinal products occurs frequently in
the diagnosis, prevention and treatment of rare diseases.
Off-label use is the use of a medicinal product for
another indication, another patient group, another dose
or by another route of administration as indicated in the
package insert. This so-called off-label use is suggested
by a similar mode of action or a similar pathology. The
competent authorities complain about this therapeutic
usage because there is no evidence of their safety and
efficacy. Payers hesitate to reimburse this non-validated
use. The only responsible person for this use is the pre-
scriber. Sometimes the patient will be asked to sign an
informed consent. Normalization of this off-label use
can only be done by the sponsor not by the medical
profession or the patient organization. Pharmaceutical
companies are not allowed to mention the off-label use
to the medical profession: recently settlements are
reached against companies to resolve allegations of off-
label promotion of their orphan pharmaceutical pro-
ducts (Tobi, Trisenox, Xyrem). Some pharmaceutical
companies bring the old substance on the market as a
so-called new “repurposed” or “rediscovered” medicinal
product with a higher price (Litak, Quenobilan, Savene,
Xenbilox). When the medicinal product is taken from
the market (deflazacort, mexiletine) the off-label users
lose their only treatment.
At the faculty of pharmacy of the University in Leuven,
a group of students performed in-depth interviews to all
the stakeholders in this process and identified the main
obstacles to regularization. The Belgian Health Care
Knowledge Center [https://kce.fgov.be/] will further
explore these recommendations and give advice to the
public authorities to take further actions. The Belgian
Minister of Health already proposed a Royal Decree to
reimburse some off-label use under restricted circum-
stances such as “unmet medical need”. EURORDIS has
launched an off-label questionnaire within their members
to explore the impact of this off-label prescribing for
patients with rare diseases: http://www.ataxia.org.uk/
news.php/234/off-label-use-of-medicines-information-
needed-from-people-with-ataxia.
Published: 11 November 2014
doi:10.1186/1750-1172-9-S1-O22
Cite this article as: Dooms: Understanding off-label use and the new
challenges. Orphanet Journal of Rare Diseases 2014 9(Suppl 1):O22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
University Hospitals Leuven, Belgium
Dooms Orphanet Journal of Rare Diseases 2014, 9(Suppl 1):O22
http://www.ojrd.com/content/9/S1/O22
© 2014 Dooms; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
